ALLO
Allogene Therapeutics Inc
Halal Rating :
Last Price
$1.81
Last updated:
Market Cap
-
7D Change
-7.18%
1 Year Change
-42.72%
Company Overview
Industries
Exchange
Next Earnings Date
Allogene Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing allogeneic T cell therapies for cancer. The company is pioneering the development of AlloCAR T therapies, which are engineered from cells of healthy donors, allowing for enhanced accessibility of cell therapy for cancer patients.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2024 | $22000.0 | $69.53m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Allogene Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.